Wegovy has raised concerns for investors in the food and beverage industry. Anheuser-Busch InBev (BUD) CEO Michel Doukeris ...

The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

For example: Eli Lilly shares fell 4.9 percent Pfizer 4.5 percent Amgen nearly 4.3 percent Novo Nordisk 3.4 percent The announcement ... PhRMA president and CEO Stephen Ubl said in a statement ...

Omega Therapeutics Inc. says its CEO, Mahesh Karande, has decided to leave the company for what it called "personal reasons,” ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of ...

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked Robert F.

Roche Holding AG is extremely optimistic that its latest experimental Alzheimer’s drug will deliver a benefit for patients, Chief Executive Officer Thomas Schinecker said, despite a track record of ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.